Research ExplorerPublicationsImpact of conditioning regimen intensity on outcomes of seco...

Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia

Standard

Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. / Nagler, Arnon; Peczynski, Christophe; Dholaria, Bhagirathbhai; Labopin, Myriam; Valerius, Thomas; Dreger, Peter; Kröger, Nicolaus; Reinhardt, Hans Christian; Finke, Jürgen; Franke, Georg-Nikolaus; Ciceri, Fabio; Verbeek, Mareike; Blau, Igor Wolfgang; Bornhäuser, Martin; Spyridonidis, Alexandros; Bug, Gesine; Bazarbachi, Ali; Schmid, Christophe; Yakoub-Agha, Ibrahim; Savani, Bipin N; Mohty, Mohamad.

In: BONE MARROW TRANSPL, Vol. 57, No. 7, 07.2022, p. 1116-1123.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Nagler, A, Peczynski, C, Dholaria, B, Labopin, M, Valerius, T, Dreger, P, Kröger, N, Reinhardt, HC, Finke, J, Franke, G-N, Ciceri, F, Verbeek, M, Blau, IW, Bornhäuser, M, Spyridonidis, A, Bug, G, Bazarbachi, A, Schmid, C, Yakoub-Agha, I, Savani, BN & Mohty, M 2022, 'Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia', BONE MARROW TRANSPL, vol. 57, no. 7, pp. 1116-1123. https://doi.org/10.1038/s41409-022-01693-8

APA

Nagler, A., Peczynski, C., Dholaria, B., Labopin, M., Valerius, T., Dreger, P., Kröger, N., Reinhardt, H. C., Finke, J., Franke, G-N., Ciceri, F., Verbeek, M., Blau, I. W., Bornhäuser, M., Spyridonidis, A., Bug, G., Bazarbachi, A., Schmid, C., Yakoub-Agha, I., ... Mohty, M. (2022). Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. BONE MARROW TRANSPL, 57(7), 1116-1123. https://doi.org/10.1038/s41409-022-01693-8

Vancouver

Nagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P et al. Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. BONE MARROW TRANSPL. 2022 Jul;57(7):1116-1123. https://doi.org/10.1038/s41409-022-01693-8

Bibtex

@article{acf57f47698849beb7fb3f64ff8b8073,
title = "Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia",
abstract = "Limited data is available on factors impacting the outcomes of second hematopoietic cell transplantation (HCT2) in patients with secondary acute myeloid leukemia (sAML). This study aimed to assess HCT2 outcome for sAML comparing reduced-intensity (RIC) to myeloablative (MAC) conditioning. Two hundred and fifteen patients were included: RIC (n = 134), MAC (n = 81). The median follow-up was 41.1 (95% CI: 26.7-69.3) and 28.5 (95% CI: 23.9-75.4) months, respectively. At two years, the relapse incidence (RI) was 58.3% versus 51.1% in RIC and MAC, respectively. The 2-year leukemia free survival (LFS) was 26.6% versus 26%, and the graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) was 16.4% versus 12.1%, while OS was 31.4% and 39.7%, for RIC and MAC respectively. MVA showed a significantly lower RI [hazard ratio (HR) = 0.46 (95% CI, 0.26-0.8, p = 0.006)] and improved LFS [HR = 0.62 (95% CI, 0.39-0.98, p = 0.042)] with MAC versus RIC. The choice of conditioning regimen did not impact non-relapse mortality [HR = 1.14 (95% CI, 0.52-2.5, p = 0.74)], overall survival (OS) [HR = 0.72 (95% CI, 0.44-1.17, p = 0.18)] or GRFS [HR = 0.89 (95% CI, 0.59-1.36, p = 0.6)]. In conclusion, MAC was associated with a lower RI and superior LFS. These results support the use of MAC for eligible patients with sAML who are being considered for HCT2.",
keywords = "Graft vs Host Disease/etiology, Hematopoietic Stem Cell Transplantation/methods, Humans, Leukemia, Myeloid, Acute, Neoplasms, Second Primary, Recurrence, Retrospective Studies, Transplantation Conditioning/methods",
author = "Arnon Nagler and Christophe Peczynski and Bhagirathbhai Dholaria and Myriam Labopin and Thomas Valerius and Peter Dreger and Nicolaus Kr{\"o}ger and Reinhardt, {Hans Christian} and J{\"u}rgen Finke and Georg-Nikolaus Franke and Fabio Ciceri and Mareike Verbeek and Blau, {Igor Wolfgang} and Martin Bornh{\"a}user and Alexandros Spyridonidis and Gesine Bug and Ali Bazarbachi and Christophe Schmid and Ibrahim Yakoub-Agha and Savani, {Bipin N} and Mohamad Mohty",
note = "{\textcopyright} 2022. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2022",
month = jul,
doi = "10.1038/s41409-022-01693-8",
language = "English",
volume = "57",
pages = "1116--1123",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia

AU - Nagler, Arnon

AU - Peczynski, Christophe

AU - Dholaria, Bhagirathbhai

AU - Labopin, Myriam

AU - Valerius, Thomas

AU - Dreger, Peter

AU - Kröger, Nicolaus

AU - Reinhardt, Hans Christian

AU - Finke, Jürgen

AU - Franke, Georg-Nikolaus

AU - Ciceri, Fabio

AU - Verbeek, Mareike

AU - Blau, Igor Wolfgang

AU - Bornhäuser, Martin

AU - Spyridonidis, Alexandros

AU - Bug, Gesine

AU - Bazarbachi, Ali

AU - Schmid, Christophe

AU - Yakoub-Agha, Ibrahim

AU - Savani, Bipin N

AU - Mohty, Mohamad

N1 - © 2022. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2022/7

Y1 - 2022/7

N2 - Limited data is available on factors impacting the outcomes of second hematopoietic cell transplantation (HCT2) in patients with secondary acute myeloid leukemia (sAML). This study aimed to assess HCT2 outcome for sAML comparing reduced-intensity (RIC) to myeloablative (MAC) conditioning. Two hundred and fifteen patients were included: RIC (n = 134), MAC (n = 81). The median follow-up was 41.1 (95% CI: 26.7-69.3) and 28.5 (95% CI: 23.9-75.4) months, respectively. At two years, the relapse incidence (RI) was 58.3% versus 51.1% in RIC and MAC, respectively. The 2-year leukemia free survival (LFS) was 26.6% versus 26%, and the graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) was 16.4% versus 12.1%, while OS was 31.4% and 39.7%, for RIC and MAC respectively. MVA showed a significantly lower RI [hazard ratio (HR) = 0.46 (95% CI, 0.26-0.8, p = 0.006)] and improved LFS [HR = 0.62 (95% CI, 0.39-0.98, p = 0.042)] with MAC versus RIC. The choice of conditioning regimen did not impact non-relapse mortality [HR = 1.14 (95% CI, 0.52-2.5, p = 0.74)], overall survival (OS) [HR = 0.72 (95% CI, 0.44-1.17, p = 0.18)] or GRFS [HR = 0.89 (95% CI, 0.59-1.36, p = 0.6)]. In conclusion, MAC was associated with a lower RI and superior LFS. These results support the use of MAC for eligible patients with sAML who are being considered for HCT2.

AB - Limited data is available on factors impacting the outcomes of second hematopoietic cell transplantation (HCT2) in patients with secondary acute myeloid leukemia (sAML). This study aimed to assess HCT2 outcome for sAML comparing reduced-intensity (RIC) to myeloablative (MAC) conditioning. Two hundred and fifteen patients were included: RIC (n = 134), MAC (n = 81). The median follow-up was 41.1 (95% CI: 26.7-69.3) and 28.5 (95% CI: 23.9-75.4) months, respectively. At two years, the relapse incidence (RI) was 58.3% versus 51.1% in RIC and MAC, respectively. The 2-year leukemia free survival (LFS) was 26.6% versus 26%, and the graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) was 16.4% versus 12.1%, while OS was 31.4% and 39.7%, for RIC and MAC respectively. MVA showed a significantly lower RI [hazard ratio (HR) = 0.46 (95% CI, 0.26-0.8, p = 0.006)] and improved LFS [HR = 0.62 (95% CI, 0.39-0.98, p = 0.042)] with MAC versus RIC. The choice of conditioning regimen did not impact non-relapse mortality [HR = 1.14 (95% CI, 0.52-2.5, p = 0.74)], overall survival (OS) [HR = 0.72 (95% CI, 0.44-1.17, p = 0.18)] or GRFS [HR = 0.89 (95% CI, 0.59-1.36, p = 0.6)]. In conclusion, MAC was associated with a lower RI and superior LFS. These results support the use of MAC for eligible patients with sAML who are being considered for HCT2.

KW - Graft vs Host Disease/etiology

KW - Hematopoietic Stem Cell Transplantation/methods

KW - Humans

KW - Leukemia, Myeloid, Acute

KW - Neoplasms, Second Primary

KW - Recurrence

KW - Retrospective Studies

KW - Transplantation Conditioning/methods

U2 - 10.1038/s41409-022-01693-8

DO - 10.1038/s41409-022-01693-8

M3 - SCORING: Journal article

C2 - 35501565

VL - 57

SP - 1116

EP - 1123

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 7

ER -